Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer : Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer

09/16/2021 | 02:32am EDT
SPECIALIZED PRESS
Thursday - September 16, 2021
Bitte JavaScript aktivieren / Please enable JavaScript



About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

*Dr. Drilon has provided speaking and consulting services to Bayer.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.

Disclaimer

Bayer AG published this content on 16 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2021 06:31:03 UTC.


© Publicnow 2021
All news about BAYER AG
10/22Mexico's agriculture minister say Mexico will not limit GMO corn imports from U.S
RE
10/22PRESS RELEASE : AiCuris announces expansion of its collaboration with Lysando with a focus..
DJ
10/21PRESS RELEASE : Pfizer and BioNTech Announce Phase -3-
DJ
10/20BAYER AG : Barclays reaffirms its Neutral rating
MD
10/20BAYER AG : UBS keeps its Buy rating
MD
10/19BAYER : Sticks To 2021 Guidance Amid Production Halt, Changing Planting Habits
MT
10/19BAYER : farmers pre-buying crop inputs as supply-chain snarls continue
RE
10/18BAYER AG : Receives a Buy rating from JP Morgan
MD
10/18BAYER : Belmora Seeks SCOTUS Review For The Second Time In Its Cross-Border Trademark Batt..
AQ
10/15CureVac Shares Down 12%
DJ
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2021 42 416 M 49 385 M 49 385 M
Net income 2021 864 M 1 005 M 1 005 M
Net Debt 2021 39 371 M 45 840 M 45 840 M
P/E ratio 2021 25,7x
Yield 2021 4,22%
Capitalization 47 471 M 55 218 M 55 270 M
EV / Sales 2021 2,05x
EV / Sales 2022 1,94x
Nbr of Employees 99 439
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 48,32 €
Average target price 61,36 €
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG0.34%55 218
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979